联环药业: 联环药业股票交易异常波动公告

Core Viewpoint - The stock of Jiangsu Lianhuan Pharmaceutical Co., Ltd. experienced abnormal trading fluctuations, with a cumulative closing price increase exceeding 20% over three consecutive trading days, prompting the company to issue a notice regarding the situation [1][2]. Group 1: Stock Trading Abnormalities - The company's stock closed with a price increase deviation of over 20% on July 4, July 7, and July 8, 2025, which is classified as abnormal trading behavior according to the Shanghai Stock Exchange regulations [1]. - The board of directors confirmed that there are no undisclosed significant matters related to major asset restructuring, share issuance, or other major transactions that could affect stock trading [2]. Group 2: Company Operations and Market Conditions - The company conducted a self-examination and confirmed that its production and operations are normal, with no significant changes in the market environment or industry policies [1]. - There are no major events identified that could significantly impact the company's stock price, and no media reports or market rumors have been found that require clarification [2]. Group 3: Board of Directors' Statement - The board of directors affirmed that there are no undisclosed matters that should be reported according to the Shanghai Stock Exchange listing rules, and previous disclosures do not require correction or supplementation [2].